Every article, report, and earnings note where MRK appears.
Merck & Co., Inc. (MRK) climbs after late-stage melanoma vaccine headlines tied to Moderna and Keytruda. The rally reflects renewed pipeline optimism, stronger sentiment, and investor focus on future oncology growth.
Five big pharma stocks are ranked in a countdown, comparing specialty franchises, profitability, valuation, growth and earnings consistency for July 2026.
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Merck & Co., Inc. (MRK) rises after positive Phase 3 lung cancer data and a favorable European regulatory opinion for a Keytruda regimen. The move reflects renewed confidence in Merck’s oncology pipeline and its ability to extend growth beyond Keytruda alone.
Merck combines elite cash generation with a growing pipeline, but KEYTRUDA still drives nearly half of sales. The stock looks like a quality compounder as new launches help reduce concentration risk.
Merck & Co., Inc. (MRK) rises after Phase 3 lung cancer data showed improved survival for a Keytruda combination. The rally comes as oncology remains the core of Merck’s growth story, with Keytruda sales still strong and full-year guidance moving higher.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate MRK ReportCancel anytime